Popular Articles
Teeth Whitening

Roche To Commence Phase III Trials With Innovative Treatment Designed To Lower Cardiovascular Risk In Diabetes Patients With Recent Heart Attack
Roche announced it will start Phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 which is uniquely designed to reduce cardiovascular morbidity and mortality in high risk patients with type 2 diabetes. This decision is supported by data from the Phase II SYNCHRONY study published today in The Lancet(1) and announced at the American Diabetes Association meeting in New Orleans. The Phase III program is anticipated to start in the second half of 2009.
generic viagra online
Study Finds Pay-For-Performance Doesn't Hurt Quality
A Veterans Affairs study found that people treated by doctors being compensated under pay-for-performance arrangements weren"t short-changed and received high-quality care. Health Day News reports that the study, which used data from both medical charts and patients" ratings of their care, "should reassure patients and the doctors who treat them." The study calms concerns that doctors might avoid patients who are very sick because their quality ratings and pay might suffer if they take the time to properly treat people with multiple conditions.
plastic surgery before after
News of the day
Stem Cell 'Daughters' Lead To Breast Cancer
Walter and Eliza Hall Institute scientists have found that a population of breast cells called luminal progenitor cells are likely to be responsible for breast cancers that develop in women carrying mutations in the gene BRCA1.
Diagnostics

Extending The Life Of An Appetite-Suppressing Peptide

The peptide alpha-MSH works in a region of the brain known as the hypothalamus to suppress appetite. A team of researchers, at Yale University School of Medicine, New Haven, and the University of California Davis, has provided new insight into the way in which levels of the active form of alpha-MSH are regulated in mice. Specifically, genetic and biochemical analysis performed by the team, led by Sabrina Diano and Craig Warden, indicated that the protein PRCP is expressed in the hypothalamus and breaks down the active form of alpha-MSH, generating a slightly smaller peptide that does not suppress food intake. Importantly, administration of PRCP inhibitors to both normal and obese mice reduced their food intake. Further, mice lacking PRCP had increased levels of the active form of alpha-MSH in the hypothalamus and were leaner and shorter than normal mice; they also did not get obese when fed a high-fat diet. The authors suggest that these data are the first step in identifying PRCP as a candidate drug target for the treatment of obesity and obesity-related disorders. Although Richard Palmiter, at the University of Washington, Seattle, also raises this intriguing possibility, he cautions that any drug would need to penetrate the brain. TITLE: Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents https://www.the-jci.org/article.php?id=37209 AUTHOR CONTACT: Sabrina Diano Yale University School of Medicine, New Haven, Connecticut, USA. Craig H. Warden University of California Davis, Davis, California, USA. ACCOMPANYING COMMENTARY TITLE: Reduced levels of neurotransmitter-degrading enzyme PRCP promote obesity https://www.the-jci.org/article.php?id=40001 AUTHOR CONTACT: Richard D. Palmiter University of Washington, Seattle, Washington, USA. Karen Honey Journal of Clinical Investigation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):